Inherited Retinal Disease:
What Can Be Done When There Is No Cure?

Being told that there is “no cure” can sound like there is nothing to do. That is not accurate. Even when no approved disease-modifying treatment exists, there are meaningful actions: confirm the diagnosis genetically, treat complications, protect remaining function, screen for trials, address syndromic health risks, use low-vision rehabilitation early, and build a support plan for work, education, mobility and family decisions.

What inherited retinal disease means

Inherited retinal diseases (IRDs) are caused by pathogenic genetic variants that affect photoreceptors, retinal pigment epithelium, retinal metabolism, cilia, synapses or related structures. The same clinical label can be caused by many genes, and variants in one gene can produce different patterns. Retinitis pigmentosa usually begins with night blindness and peripheral-field loss; Stargardt disease often affects central vision; cone-rod dystrophy may begin with central, color and light-sensitivity problems; Usher syndrome combines retinal degeneration with hearing loss.

More than 280 genes have been associated with IRDs, and additional genes continue to be discovered. This diversity is why the exact molecular diagnosis matters for prognosis, family counseling, eligibility for approved therapy and clinical-trial matching.

Step 1: confirm the phenotype and obtain genetic testing

An inherited-retinal-disease specialist may use dilated examination, OCT, fundus autofluorescence, visual fields, electroretinography, color testing, photography and family history to define the phenotype. Genetic testing can identify or narrow the cause, but it does not produce an answer in every patient. Current sequencing approaches often solve approximately half to three-quarters of cases, depending on the population, test and diagnostic criteria.

Testing should be paired with genetic counseling. Results can affect relatives, reproductive decisions and eligibility for trials. A “variant of uncertain significance” is not the same as a confirmed cause. Periodic reanalysis may be valuable as databases and interpretation improve.

Step 2: determine whether an approved gene therapy applies

LUXTURNA (voretigene neparvovec-rzyl) is FDA approved for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Eligibility also depends on the presence of sufficient viable retinal cells and evaluation at a specialized treatment center. It is not a treatment for all retinitis pigmentosa, all Leber congenital amaurosis or all inherited retinal disease.

As of July 2026, most IRDs still do not have an FDA-approved gene-specific therapy. The absence of an approval today does not mean research is inactive. It means patients should be matched by gene, disease stage and trial criteria rather than marketed a generic “gene therapy.”

Step 3: understand the treatment pipeline

The inherited retinal disease treatment pipeline includes gene replacement, RNA therapies, gene editing, optogenetics, cell-based treatments and neuroprotective strategies. Some approaches target a specific gene, while others aim to preserve or restore function across multiple conditions. Most remain investigational, and their suitability depends on the genetic diagnosis, disease stage and number of surviving retinal cells.

What the research does not establish

1. That an herb shown to protect cells in a laboratory will preserve vision in a human eye.
2. That one traditional formula treats every stage or subtype of glaucoma, AMD, diabetic retinopathy or retinal degeneration.
3. That a short-term change in acuity or circulation equals slower long-term structural progression.
4. That “natural” products are automatically safer than prescription medicine.
5. That a product sold under the same common name contains the same species, dose, contaminants or active compounds.
6. That an individualized formula can be assumed effective because one standardized product was studied.

Herbal safety is part of the treatment - not an afterthought

NCCIH warns that some Ayurvedic preparations may contain lead, mercury or arsenic, and that some Chinese herbal products have been contaminated with heavy metals, pesticides, microorganisms, undeclared drugs or the wrong herb. Traditional products can also cause liver injury, kidney injury, allergic reactions, blood-pressure changes, glucose changes or bleeding.
Ayurvedic preparations and Traditional products should be from reliable sources which monitors and tests for contaminations.

How Netra Restoration Therapy uses traditional medicine responsibly

Within NRT, TCM and Ayurvedic interventions are intended to be individualized according to diagnosis, systemic health, medications, constitution or pattern, and functional goals. The modern clinical rationale may include support for inflammatory regulation, oxidative balance, microcirculation, autonomic function, digestion, sleep, stress and metabolic health.

The program makes a clear claim boundary: traditional medicine may support the patient and may influence biological pathways, but it does not replace pressure control, anti-VEGF treatment, cross-linking, immunosuppression, surgery, genetic counseling or urgent ophthalmic care. Where condition-specific clinical evidence is weak, the website will say so.

A practical evidence-and-safety checklist

A practical safety checklist begins with clearly identifying the product or procedure, documenting all ingredients and doses, and reviewing possible interactions and medical risks. Products should come from traceable, tested suppliers, treatment goals should be measurable, and standard ophthalmic care should continue. Any new symptoms or abnormal findings should prompt treatment to stop and be investigated.

1. Name the exact product or procedure, not just “Ayurveda” or “Chinese medicine.”
2. Document every ingredient, species, part used, dose and duration.
3. Review prescription drugs, over-the-counter medicines and supplements for interactions.
4. Screen for pregnancy, allergies, liver or kidney disease, bleeding risk and autoimmune conditions.
5. Use suppliers with traceability and appropriate contaminant testing.
6. Define the intended outcome and how it will be measured.
7. Continue ophthalmic monitoring and established treatment.
8. Stop and investigate new symptoms or abnormal laboratory findings.

Frequently Asked Questions

Selected References for Scientific Support

• National Center for Complementary and Integrative Health. Ayurvedic Medicine: In Depth. Source
• National Center for Complementary and Integrative Health. Traditional Chinese Medicine: What You Need To Know. Source
• National Center for Complementary and Integrative Health. Herb-Drug Interactions. Source
• Li Y, et al. Traditional Chinese medicine approaches to age-related macular degeneration: a review. 2022. Source
• Jiawei Simiaoyongan granules in noninfectious anterior uveitis: randomized controlled study. 2026. Source